Show simple item record

dc.contributor.authorCoombs, Geoffrey W
dc.contributor.authorDaley, Denise A
dc.contributor.authorLee, Yung Thin
dc.contributor.authorPang, Stanley
dc.contributor.authorBell, Jan M
dc.contributor.authorTurnidge, John D
dc.contributor.authorPang, Stanley
dc.contributor.authorCollignon, Peter
dc.contributor.authorBradbury, Susan
dc.contributor.authorGottlieb, Thomas
dc.contributor.authorRobertson, Graham
dc.contributor.authorBranley, James
dc.contributor.authorBarbaro, Donna
dc.contributor.authorNimmo, Graeme
dc.contributor.authoret al.
dc.date.accessioned2020-12-11T04:27:06Z
dc.date.available2020-12-11T04:27:06Z
dc.date.issued2018
dc.identifier.issn0725-3141en_US
dc.identifier.urihttp://hdl.handle.net/10072/400181
dc.description.abstractFrom 1 January to 31 December 2015, 31 Australian institutions participated in the Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP). The aim of ASSOP 2015 was to determine the proportion of Staphylococcus aureus bacteraemia (SAB) isolates in Australia that are antimicrobial resistant, with particular emphasis on susceptibility to methicillin and to characterise the molecular epidemiology of the methicillin-resistant isolates. Overall 18.2% of the 2,399 SAB episodes were methicillin-resistant. The 30-day all-cause mortality associated with methicillin-resistant SAB was 18.8% which was not significantly higher than the 15.1% mortality associated with methicillinsensitive SAB. With the exception of the β-lactams and erythromycin, antimicrobial resistance in methicillin sensitive S. aureus (MSSA) remains rare. However, in addition to the β-lactams, approximately 50% of methicillin-resistant S. aureus (MRSA) were resistant to erythromycin and ciprofloxacin and approximately 15% resistant to co-trimoxazole, tetracycline and gentamicin. When applying the EUCAST breakpoints teicoplanin resistance was detected in two S. aureus isolates. Resistance was not detected for vancomycin and linezolid. Resistance to non-beta-lactam antimicrobials was largely attributable to two healthcare-associated MRSA clones; ST22-IV [2B] (EMRSA-15) and ST239-III [3A] (Aus-2/3 EMRSA). ST22-IV [2B] (EMRSA-15) is the predominant healthcare-associated clone in Australia. Sixty-seven percent of methicillin-resistant SAB were due to community-associated clones. Although polyclonal, almost 43% of community-associated clones were characterised as ST93-IV [2B] (Queensland CA-MRSA) and ST1-IV [2B] (WA1). CA-MRSA in particular the ST45-V [5C2&5] (WA84) clone has acquired multiple antimicrobial resistance determinants including ciprofloxacin, erythromycin, clindamycin, gentamicin and tetracycline. As CA-MRSA is well established in the Australian community it is important antimicrobial resistance patterns in community and healthcare-associated SAB are monitored as this information will guide therapeutic practices in treating S. aureus sepsis.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglishen_US
dc.language.isoeng
dc.publisherAustralian Government. Dept of Health & Ageingen_US
dc.publisher.urihttps://www1.health.gov.au/internet/main/publishing.nsf/Content/cdi-2018-indexen_US
dc.relation.ispartofjournalCommunicable Diseases Intelligenceen_US
dc.relation.ispartofvolume42en_US
dc.subject.fieldofresearchClinical Sciencesen_US
dc.subject.fieldofresearchPublic Health and Health Servicesen_US
dc.subject.fieldofresearchcode1103en_US
dc.subject.fieldofresearchcode1117en_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsInfectious Diseasesen_US
dc.subject.keywordsAustralian Group on Antimicrobial Resistance (AGAR)en_US
dc.subject.keywordsantimicrobial resistance surveillance, Staphylococcus aureus, methicillin sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), bacteraemiaen_US
dc.titleAustralian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2015en_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationCoombs, GW; Daley, DA; Lee, YT; Pang, S; Bell, JM; Turnidge, JD; Pang, S; Collignon, P; Bradbury, S; Gottlieb, T; Robertson, G; Branley, J; Barbaro, D; Nimmo, G;et al., Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2015, Communicable Diseases Intelligence, 2018, 42en_US
dc.date.updated2020-12-11T03:57:03Z
dc.description.versionVersion of Record (VoR)en_US
gro.rights.copyright© 2018 Australian Government. The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.en_US
gro.hasfulltextFull Text
gro.griffith.authorNimmo, Graeme R.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record